
Delphine Diagnostics Inc. is a New Jersey-based startup focused on developing and supplying advanced diagnostic products and AI/ML healthcare platforms to expedite the diagnosis and treatment of infectious diseases, particularly sepsis. Their offerings include sepsis diagnostic test kits utilizing real-time PCR technology and an AI/ML tool for clinical decision support. The company aims to revolutionize infection diagnosis by enabling faster, more accurate identification of pathogens and host markers, leading to personalized patient care, optimized antimicrobial usage, and improved patient outcomes. The team comprises industry-experienced professionals in biomedical science, data analytics, and market development. They are developing an AI/ML application to aid clinicians in selecting appropriate antimicrobial regimens.

Delphine Diagnostics Inc. is a New Jersey-based startup focused on developing and supplying advanced diagnostic products and AI/ML healthcare platforms to expedite the diagnosis and treatment of infectious diseases, particularly sepsis. Their offerings include sepsis diagnostic test kits utilizing real-time PCR technology and an AI/ML tool for clinical decision support. The company aims to revolutionize infection diagnosis by enabling faster, more accurate identification of pathogens and host markers, leading to personalized patient care, optimized antimicrobial usage, and improved patient outcomes. The team comprises industry-experienced professionals in biomedical science, data analytics, and market development. They are developing an AI/ML application to aid clinicians in selecting appropriate antimicrobial regimens.
Focus: Sepsis diagnostics and AI/ML clinical decision support
Flagship product: Real-time PCR sepsis diagnostic assay (proof-of-concept)
AI capability: Developing an AI/ML app for real-time clinician decision support
Founded: 2020
Recent funding: Grant from Commission on Science, Innovation and Technology (2025-03-05)
Team size: Approximately 7 employees
Rapid diagnosis of infectious diseases with emphasis on sepsis and clinical decision support for antimicrobial selection.
2020
Medical Equipment Manufacturing
Amount undisclosed
“Grant from Commission on Science, Innovation and Technology”
| Company |
|---|